<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813601</url>
  </required_header>
  <id_info>
    <org_study_id>ATLAS2030CLI-I</org_study_id>
    <nct_id>NCT04813601</nct_id>
  </id_info>
  <brief_title>Rehabilitative Effect of the Use of a Gait Exoskeleton in Patients With Neuromuscular Disease or Cerebral Palsy</brief_title>
  <official_title>Estudio Piloto de Una Serie de Casos Para Evaluar el Efecto Rehabilitador Del Uso de un Exoesqueleto de Marcha en Pacientes Con patología Neuromuscular o parálisis Cerebral</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MarsiBionics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MarsiBionics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicentric study is to assess the rehabilitative effect derived from&#xD;
      the use of the ATLAS exoskeleton in children with neuromuscular diseases or cerebral palsy&#xD;
      and with a level of less than 3 or less in the Functional Ambulation Classification (FAC) as&#xD;
      a consequence of their disease, as well as the assessment of other physical, functional and&#xD;
      quality of life parameters of interest. For this purpose, the exoskeleton will be used as a&#xD;
      rehabilitation and walking assistance tool.&#xD;
&#xD;
      Before starting the study programme and if deemed necessary, a preliminary phase consisting&#xD;
      of 1 to 3 sessions will be carried out during which the patient will be shown the exoskeleton&#xD;
      for the first time and it will be considered whether any improvements to the different parts&#xD;
      of the device or the software are necessary to increase the ergonomics and comfort of the&#xD;
      patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are:&#xD;
&#xD;
        -  Objective 1: To assess the safety and physical and physiological tolerance of the child&#xD;
           to the activity performed with the exoskeleton in the rehabilitation sessions.&#xD;
&#xD;
        -  Objective 2:&#xD;
&#xD;
        -  To assess the safety of a progressive treatment algorithm to achieve the safe&#xD;
           progression of patients throughout the therapy&#xD;
&#xD;
        -  To assess whether an improvement is achieved in parameters related to the physical&#xD;
           rehabilitation of the patient using the exoskeleton, in respiratory capacity,&#xD;
           self-perceived quality of life (physical and emotional well-being and self-esteem) as&#xD;
           well as to assess the effectiveness of a psychological intervention to provide support&#xD;
           in coping with the situation of using the device for the first time in those children&#xD;
           who have not used it before.&#xD;
&#xD;
      The time period of the study will be as long as necessary to reach the desired number of&#xD;
      participants, in this case 10 children (N=10). The participants will be patients affected by&#xD;
      neuromuscular diseases or cerebral palsy and will be selected on the basis of the following&#xD;
      inclusion/exclusion criteria:&#xD;
&#xD;
      Inclusion criteria: 1. Children with neuromuscular disease or cerebral palsy who present gait&#xD;
      disturbances or no gait disturbance. 2. Children between 3 and 11 years of age.&#xD;
&#xD;
      Exclussion criteria: not fulfil the usage criteria of the device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscular balance</measure>
    <time_frame>1 month</time_frame>
    <description>Strength measured in Newtons with a Hand-Held Dinamometer for elbow flexion, neck lateralization, ankle plantarflexion and dorsiflexion, knee flexion and extension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expanded Hammersmith Functional Motor Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Motor functionality measured for children with Spinal Muscular Atrophy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gross Motor Function Measure 88 (GMFM-88)</measure>
    <time_frame>3 months</time_frame>
    <description>Motor functionality measured for children with Cerebral Palsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>1 day</time_frame>
    <description>Respiratory rate measured manually in breaths per minute using chronometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>1 day</time_frame>
    <description>Measured in beats per minute using vital sign monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxigen Saturation</measure>
    <time_frame>1 day</time_frame>
    <description>Measured in %O2 using vital sign monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood preasure</measure>
    <time_frame>1 day</time_frame>
    <description>measured in mmHg with a sphyngomanometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory functional parameters</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by Spirometer (volumes measured in litres and pressures in mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of life iof the children measured using the KINDL questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Joint range of motion</measure>
    <time_frame>1 month</time_frame>
    <description>Range of motion in degrees of hip, knee and ankle movements using a manual goniometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Revised Upper Limb Module (RULM)</measure>
    <time_frame>3 months</time_frame>
    <description>Upper limb quality of movement using RULM scale for Spinal Muscular Atrophy children</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality Upper Extremity Skill test (QUEST)</measure>
    <time_frame>3 months</time_frame>
    <description>Upper limb quality of movement using QUEST scale for cerebral palsy children</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Functional Independence Measure for Children (WeeFim)</measure>
    <time_frame>3 months</time_frame>
    <description>WeeFim scale for CP children.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Egen Klassifikation</measure>
    <time_frame>3 months</time_frame>
    <description>Functional ability measured using EK2 scale for SMA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin integrity</measure>
    <time_frame>1 day</time_frame>
    <description>Skin alterations assessing their localization, size (centimeters), redness and temperature increase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue</measure>
    <time_frame>1 day</time_frame>
    <description>Patient fatigue measured by Borg fatigue scale for children ages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>1 day</time_frame>
    <description>Patient pain measured by EVA faces scale for children ages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Flow cough</measure>
    <time_frame>1 week</time_frame>
    <description>Measured in litres per minute using a Peak flowmeter</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Neuromuscular Diseases</condition>
  <condition>Cerebral Palsy</condition>
  <condition>SMA II</condition>
  <arm_group>
    <arm_group_label>Robot Asissted Gait Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The rehabilitation sessions will be carried out by a physiotherapist trained in rehabilitation with the ATLAS 2030 exoskeleton and will also have the technical supervision of personnel specialised in the handling of the laboratory and the robotic device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ATLAS 2030</intervention_name>
    <description>The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.</description>
    <arm_group_label>Robot Asissted Gait Training</arm_group_label>
    <other_name>Robot Asissted Gait Training</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children with neuromuscular disease or cerebral palsy who have gait disturbance or no&#xD;
             gait.&#xD;
&#xD;
          -  Children between 3 and 11 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight&gt; 35 kg&#xD;
&#xD;
          -  Femoral length (from the axis of the hip joint in the sagittal plane to the axis of&#xD;
             the knee joint in the same plane) &lt;23 cm or &gt;38 cm for size M and from 31 cm to 40 cm&#xD;
             for size L&#xD;
&#xD;
          -  Stem length (from the axis of the knee joint in the sagittal plane to the axis of the&#xD;
             ankle joint in the same plane) &lt;23 or &gt;32 cm for size M and from or &gt;39 cm for size L&#xD;
&#xD;
          -  Distance between great trochanters &lt;24 or &gt;35 cm for size M and &lt;25 cm or &gt;35 cm for&#xD;
             size L&#xD;
&#xD;
          -  Inability to understand simple commands, to cooperate actively in therapy, or&#xD;
             inability to express basic needs&#xD;
&#xD;
          -  Spasticity measured with the Modified Ashworth Scale greater than or equal to 3 in the&#xD;
             lower limbs&#xD;
&#xD;
          -  Scoliosis &gt; 25° without the possibility of wearing a brace&#xD;
&#xD;
          -  Skin alteration where direct contact between the patient's skin and the exoskeleton is&#xD;
             not recommended&#xD;
&#xD;
          -  Limitation of passive range of motion at the knee or hip joint &gt; 20 degrees&#xD;
&#xD;
          -  Osteoporosis that may induce a bone fracture when low intensity physical activity is&#xD;
             performed&#xD;
&#xD;
          -  Any other medical condition that may be a risk to the patient's safety and well-being&#xD;
             in relation to low intensity physical exercise&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mercedes Martinez, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marsi Bionics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Destarac</last_name>
    <phone>914 90 00 90</phone>
    <email>marie.destarac@marsibionics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MarsiCare</name>
      <address>
        <city>Arganda Del Rey</city>
        <state>Madrid</state>
        <zip>28500</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Ramos</last_name>
      <phone>918 71 19 00</phone>
      <email>jaime.ramos@csic.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gait Exoskeleton</keyword>
  <keyword>Robotics</keyword>
  <keyword>Children</keyword>
  <keyword>ATLAS 2030</keyword>
  <keyword>Neuromuscular disease</keyword>
  <keyword>Cerebral Palsy</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

